AZ trial announcement good news in the short term for SP impact and some revenue. However once again AZ clinical trials a distraction from the focus ADR need to have on commercialisation. Their trial involvement has done nothing to support commercialisation - it has not for 20 years, it wont do it now, the AZ relationship is a distraction they admitted in the past that has held them back and continues to do so.
ADR like to push their supply of devices into trials, however I have yet to see any data that helps ADR commercially. They themselves have in the past admitted that AZ contract and a distraction and that they were going to move a way from their reliance on AZ and forge their own commercial path. That never materialised and they contiue to hold onto the AZ apron strings as they have nothing else to say.
I would suspect that as per usual there will be no AZ announcement on the trial WRT ADR, there is no quote form AZ, they will probably not participate in the CR, they have not since the IPO in 2015 as far as I can see and as this trial will take at least 3 years no commencail impact thats meaningful when we need it.
ADR announced a AZ clinical supply contract in Sept 2021 which was transitioned to a third party June 2022 for a two year study - has that completed, what was the outcome - no announcement on that WRT results or impact
Sept 2022 announced another study with Washington University - nothing since then
ADR Price at posting:
2.3¢ Sentiment: None Disclosure: Held
